Navigation Links
Peregrine Pharmaceuticals Appoints Former Genentech Senior Executive Dr. Robert Garnick as Head of Regulatory Affairs
Date:10/19/2009

TUSTIN, Calif., Oct. 19 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHMD) today announced that Dr. Robert Garnick has joined the company as the head of regulatory affairs. Dr. Garnick was formerly the senior vice president of regulatory, quality and compliance at Genentech. During his 24-year career at Genentech, he was responsible for 17 new product approvals including most of the company's top selling monoclonal antibody therapeutics such as Rituxan®, Herceptin®, Avastin® and Lucentis®. Dr. Garnick will be responsible for overseeing Peregrine's interactions with the U.S. FDA and regulatory agencies around the world, and will lead the development of the company's regulatory strategies for advancing its novel monoclonal antibody-based treatments for cancer and infectious diseases.

"Rob has an unparalleled track record in the biotechnology and pharmaceutical industry, having led the regulatory, quality and compliance strategy for developing many of the most successful monoclonal antibody therapeutics currently on the market representing multiple disease areas," said Steven W. King, president and CEO of Peregrine. "His profound understanding of every aspect of the regulatory process and how it impacts clinical design and drug development is already proving invaluable as we prepare for the next stage of clinical development for our innovative drug candidates bavituximab and Cotara®. We have made considerable progress over the past few years in our clinical programs and bringing Rob's expertise and experience on board at this critical time is a significant development for the company."

Dr. Garnick has over 30 years of experience in drug and biologic pharmaceutical development, including 24 years at Genentech helping to build the biotechnology industry. Dr. Garnick joined Ge
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Pharmaceuticals Forms Anti-Viral Research Group to Oversee Its Anti-PS Infectious Disease Collaborations
2. Interim Phase II Data Presented at XIV World Congress of Neurological Surgery Supports Potential of Peregrines Cotara(R) for Treatment of Brain Cancer
3. Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials
4. Peregrine Pharmaceuticals Completes Patient Enrollment in its Phase II Trial of Bavituximab Plus Docetaxel in Breast Cancer Patients
5. Affitech-Discovered Anti-PS Antibodies in Development by Peregrine Pharmaceuticals Show Excellent Functionality in Preclinical Studies
6. Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrines Fully Human Anti-PS Antibody in Prostate Cancer Model
7. Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrines PS-Targeting Antibodies
8. Peregrine Pharmaceuticals Reports Positive Preliminary Data From Phase II Bavituximab Lung Cancer Trial
9. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial
10. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
11. Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... January 23, 2015 Heptares Therapeutics, the clinical-stage ... announce that the Malcolm Campbell Memorial Prize for ... President of Chemistry), Fiona Marshall (Chief Scientific Officer ... and co-founder) for the seminal contributions to GPCR drug discovery ...
(Date:1/22/2015)... , Jan. 22, 2015  BiOptix is pleased to announce ... Vice President of Chemistry and Biochemistry. Scott joins the company ... Pharmaceuticals, and Amgen throughout the course of his nearly ... "Scott is a nationally recognized thought leader in ...
(Date:1/22/2015)... ON , Jan. 22, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. ... with a focus on Omega-3 therapies for cardiovascular disease and ... of the Company,s accomplishments in 2014 and its outlook for ... Dear Fellow Shareholders, We would like to ...
Breaking Medicine Technology:Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7
... Jan. 19, 2011 RFID Journal features ... Someone can live or die depending on the ... agree leveraging better tracking of a drug,s expiration dates, ... levels, all performed in REAL TIME, would assist in ...
... PRINCETON, N.J., Jan. 18, 2011 Pharmasset, Inc. (Nasdaq: ... commenced an underwritten public offering, subject to market and ... pursuant to an effective shelf registration statement.  Of the ... the selling stockholders are selling 1,000,000 shares.  Pharmasset intends ...
Cached Medicine Technology:MEPS Real Time's New RFID Drug Management System Provides Critical Error Solution for California Hospital 2Pharmasset Announces Proposed Public Offering of Common Stock 2Pharmasset Announces Proposed Public Offering of Common Stock 3
(Date:1/22/2015)... Deer Path of Huntley -- a BMA affordable assisted living ... p.m. to 4 p.m. on Feb. 13. , The community, which ... with physical disabilities between the ages of 22 and 64. , ... sweetheart-themed karaoke. , For more information about the event or Deer ...
(Date:1/22/2015)... Hawley, PA (PRWEB) January 22, 2015 Woodloch ... Pocono Mountains, has been selected by TripAdvisor as the number ... and the 6th best in the world for their annual ... online travel community . The website is home to ...
(Date:1/22/2015)... Angelweddingdress is a famous wedding dress company offering ... follow it on Facebook, Twitter, and Pinterest. The fans will ... draws a lottery every week. , Moreover, the company has ... Click Angelweddingdress homepage for more information. , ...
(Date:1/22/2015)... A new white paper by The ... in the long-term care environment as well as provides ... The paper, “The Power of Person-Centeredness in Long-Term Care: ... of the patient, resident and family experience in long-term ...
(Date:1/22/2015)... Joan Lunden, award-winning American journalist, beloved ... upcoming 32nd Annual Miami Breast Cancer Conference ... LLC (PER®) , shares that “a fast-growing, virulent” cancer ... she had not followed up her clean mammogram with ...
Breaking Medicine News(10 mins):Health News:Deer Path of Huntley Affordable Assisted Living to Host Valentine's Day Happy Hour 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6
... /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (the ... final results of its separate concurrent fixed price exchange offers ... any and all of the approximately $118.9 million outstanding principal ... The Exchange Offers expired at 5:00 p.m., New York ...
... As President Obama prepares to sign a bill giving ... tobacco industry, a new study from Harvard School of ... continually changed the ingredients and the design of their ... acceptable product variance guidelines. The result, say the researchers, ...
... The Damon Runyon Cancer Research Foundation, a non-profit ... and innovative cancer research, named 17 new Damon ... Committee review. The recipients of this prestigious, three-year ... translational cancer research in the laboratories of leading ...
... in Williamson County ... Round Rock Medical Center today announced that the hospital will seek ... Williamson County. , , "St. David,s Round Rock Medical Center ... has the busiest emergency department in the City of Round Rock ...
... their choice , FRIDAY, June 19 (HealthDay News) -- ... can,t list any actual benefits, a new British study ... BMC Public Health , stemmed from interviews that University ... sports center. , "The majority of participants believed that ...
... WLP ) will release second quarter 2009 financial results on July 29, ... and its outlook during a conference call at 8:30 a.m. EDT that same ... its start with the following numbers: , , , ... 800-475-6701 (Domestic Replay), ...
Cached Medicine News:Health News:Cell Therapeutics Announces Final Results of its Fixed Price Exchange Offers for Any and All of its $118.9 Million Convertible Notes Outstanding 2Health News:Cell Therapeutics Announces Final Results of its Fixed Price Exchange Offers for Any and All of its $118.9 Million Convertible Notes Outstanding 3Health News:Study finds that tobacco companies changed design of cigarettes without alerting smokers 2Health News:Damon Runyon Cancer Research Foundation awards prestigious fellowships to 17 top young scientists 2Health News:Damon Runyon Cancer Research Foundation awards prestigious fellowships to 17 top young scientists 3Health News:Damon Runyon Cancer Research Foundation awards prestigious fellowships to 17 top young scientists 4Health News:Damon Runyon Cancer Research Foundation awards prestigious fellowships to 17 top young scientists 5Health News:St. David's Round Rock Medical Center to Seek Level II Trauma Designation 2Health News:St. David's Round Rock Medical Center to Seek Level II Trauma Designation 3Health News:St. David's Round Rock Medical Center to Seek Level II Trauma Designation 4Health News:WellPoint to Hold Conference Call and Webcast to Discuss Second Quarter Results on July 29, 2009 2